675 related articles for article (PubMed ID: 31046547)
1. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K
MAbs; 2019; 11(4):666-680. PubMed ID: 31046547
[TBL] [Abstract][Full Text] [Related]
2. Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for the engineering of bispecifics.
Ching KH; Berg K; Reynolds K; Pedersen D; Macias A; Abdiche YN; Harriman WD; Leighton PA
MAbs; 2021; 13(1):1862451. PubMed ID: 33491549
[TBL] [Abstract][Full Text] [Related]
3. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
4. Biophysical and Immunological Characterization and
Hutchins B; Starling GC; McCoy MA; Herzyk D; Poulet FM; Dulos J; Liu L; Kang SP; Fayadat-Dilman L; Hsieh M; Andrews CL; Ayanoglu G; Cullen C; Malefyt RW; Kastelein RA; Saux SL; Lee J; Li S; Malashock D; Sadekova S; Soder G; van Eenennaam H; Willingham A; Yu Y; Streuli M; Carven GJ; van Elsas A
Mol Cancer Ther; 2020 Jun; 19(6):1298-1307. PubMed ID: 32229606
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy.
Issafras H; Fan S; Tseng CL; Cheng Y; Lin P; Xiao L; Huang YJ; Tu CH; Hsiao YC; Li M; Chen YH; Ho CH; Li O; Wang Y; Chen S; Ji Z; Zhang E; Mao YT; Liu E; Yang S; Jiang W
PLoS One; 2021; 16(12):e0257972. PubMed ID: 34972111
[TBL] [Abstract][Full Text] [Related]
6. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy.
Fromm G; de Silva S; Johannes K; Patel A; Hornblower JC; Schreiber TH
J Immunother Cancer; 2018 Dec; 6(1):149. PubMed ID: 30563566
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
[TBL] [Abstract][Full Text] [Related]
8. An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.
Khedri M; Abnous K; Rafatpanah H; Ramezani M
J Recept Signal Transduct Res; 2018 Feb; 38(1):31-36. PubMed ID: 29252078
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD1 'SHR-1210' aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement.
Finlay WJJ; Coleman JE; Edwards JS; Johnson KS
MAbs; 2019 Jan; 11(1):26-44. PubMed ID: 30541416
[TBL] [Abstract][Full Text] [Related]
10. CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy.
Li F; Li J; Yin K; Zhang J; Li ZH; Lu L; Bao YW; Qin Z; Zheng Y; Yang BT; Li J; Wang X
Acta Pharmacol Sin; 2021 Jan; 42(1):142-148. PubMed ID: 32467569
[TBL] [Abstract][Full Text] [Related]
11. Expression of programmed death 1 ligands by murine T cells and APC.
Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
[TBL] [Abstract][Full Text] [Related]
12. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
13. Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework.
Hanf KJ; Arndt JW; Chen LL; Jarpe M; Boriack-Sjodin PA; Li Y; van Vlijmen HW; Pepinsky RB; Simon KJ; Lugovskoy A
Methods; 2014 Jan; 65(1):68-76. PubMed ID: 23816785
[TBL] [Abstract][Full Text] [Related]
14. A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity.
Luan Y; Chai D; Peng J; Ma S; Wang M; Ma H; Li X; Fu S; Pan X; Wang X; Qin S; Xu T
Int Immunopharmacol; 2016 Feb; 31():248-56. PubMed ID: 26773772
[TBL] [Abstract][Full Text] [Related]
15. Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models.
DeAngelis N; Ferrante C; Powers G; Sendecki J; Mattson B; Pizutti D; Packman K; Wang W; Trouba K; Nanjunda R; Wheeler J; Brittingham R; Wu SJ; Luo J; Lorenzi MV; Verona RI
Cancer Chemother Pharmacol; 2022 Apr; 89(4):515-527. PubMed ID: 35298699
[TBL] [Abstract][Full Text] [Related]
16. Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation.
Wang M; Wang J; Wang R; Jiao S; Wang S; Zhang J; Zhang M
Commun Biol; 2019; 2():392. PubMed ID: 31667366
[TBL] [Abstract][Full Text] [Related]
17. Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture.
Bogen JP; Carrara SC; Fiebig D; Grzeschik J; Hock B; Kolmar H
Front Immunol; 2021; 12():669496. PubMed ID: 34040611
[TBL] [Abstract][Full Text] [Related]
18. High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells.
Liang Z; Li Y; Tian Y; Zhang H; Cai W; Chen A; Chen L; Bao Y; Xiang B; Kan H; Li Y
Cancer Lett; 2019 Apr; 447():164-173. PubMed ID: 30677447
[TBL] [Abstract][Full Text] [Related]
19. Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy.
Liu H; Guo L; Zhang J; Zhou Y; Zhou J; Yao J; Wu H; Yao S; Chen B; Chai Y; Qi J; Gao GF; Tan S; Feng H; Yan J
MAbs; 2019; 11(4):681-690. PubMed ID: 30892132
[TBL] [Abstract][Full Text] [Related]
20. Humanization of a phosphothreonine peptide-specific chicken antibody by combinatorial library optimization of the phosphoepitope-binding motif.
Baek DS; Kim YS
Biochem Biophys Res Commun; 2015 Jul; 463(3):414-20. PubMed ID: 26036575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]